التفاصيل البيبلوغرافية
| العنوان: |
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial). |
| المؤلفون: |
Kähler, Katharina C., Hüning, S., Nashan, D., Meiss, F., Rafei-Shamsabadi, D. A., Rissmann, H., Colapietro, C., Livingstone, E., Maul, L. V., Heppt, M., Hassel, J. C., Gutzmer, R., Loquai, C., Heinzerling, L., Sachse, M. M., Bohne, A. S., Moysig, L., Peters, W., Rusch, J., Blome, C. |
| المصدر: |
Journal of Cancer Research & Clinical Oncology; Oct2023, Vol. 149 Issue 13, p11705-11718, 14p |
| مصطلحات موضوعية: |
MELANOMA, IMMUNE checkpoint inhibitors, CANCER relapse, PATIENTS' attitudes, PATIENT preferences |
| مستخلص: |
Purpose: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free survival (DFS). Due to specific side effects, the choice of treatment is very often driven by the risk for toxicity. This study addressed for the first time in a multicenter setting the attitudes and preferences of melanoma patients for adjuvant treatment with (c)ICI and TT. Methods: In this study ("GERMELATOX-A"), 136 low-risk melanoma patients from 11 skin cancer centers were asked to rate side effect scenarios typical for each (c)ICI and TT with mild-to-moderate or severe toxicity and melanoma recurrence leading to cancer death. We asked patients about the reduction in melanoma relapse and the survival increase at 5 years they would require to tolerate defined side-effects. Results: By VAS, patients on average valued melanoma relapse worse than all scenarios of side-effects during treatment with (c)ICI or TT. In case of severe side effects, patients required a 15% higher rate of DFS at 5 years for (c)ICI (80%) compared to TT (65%). For survival, patients required an increase of 5–10% for melanoma survival during (c)ICI (85%/80%) compared to TT (75%). Conclusion: Our study demonstrated a pronounced variation of patient preferences for toxicity and outcomes and a clear preference for TT. As adjuvant melanoma treatment with (c)ICI and TT will be increasingly implemented in earlier stages, precise knowledge of the patient perspective can be helpful for decision making. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cancer Research & Clinical Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |